ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
ALX Oncology (NASDAQ:ALXO) announced a significant leadership change as Dr. Barbara Klencke, a current board member, has been appointed as Interim Chief Medical Officer (CMO), replacing Dr. Alan Sandler who will return to his position on the company's Board of Directors.
Dr. Klencke brings over 30 years of experience in oncology and drug development, with notable achievements including serving as CMO at Sierra Oncology until its GSK acquisition in 2022. She will oversee the development of ALX's evorpacept and ALX2004 clinical programs, focusing on the company's CD47 blocker and EGFR-targeted antibody-drug conjugate (ADC) pipeline.
ALX Oncology (NASDAQ:ALXO) ha annunciato un importante cambio di leadership: la Dott.ssa Barbara Klencke, attuale membro del consiglio, è stata nominata Interim Chief Medical Officer (CMO), sostituendo il Dott. Alan Sandler che tornerà a ricoprire il proprio ruolo nel Consiglio di Amministrazione dell’azienda.
La Dott.ssa Klencke vanta oltre 30 anni di esperienza nel settore oncologico e nello sviluppo di farmaci, con successi rilevanti tra cui il ruolo di CMO presso Sierra Oncology fino all'acquisizione da parte di GSK nel 2022. guiderà lo sviluppo dei programmi clinici evorpacept e ALX2004 di ALX, concentrandosi sul blocker CD47 dell’azienda e sull’anticorpo-fago coniugato a bersaglio EGFR (ADC) della pipeline.
ALX Oncology (NASDAQ:ALXO) anunció un cambio significativo en su liderazgo: la Dra. Barbara Klencke, actual miembro de la junta, ha sido designada como Interim Chief Medical Officer (CMO), reemplazando al Dr. Alan Sandler quien volverá a su puesto en la Junta Directiva de la empresa.
La Dra. Klencke aporta más de 30 años de experiencia en oncología y desarrollo de fármacos, con logros notables como haber sido CMO en Sierra Oncology hasta su adquisición por parte de GSK en 2022. Supervisará el desarrollo de los programas clínicos evorpacept y ALX2004 de ALX, enfocándose en el bloqueo de CD47 de la empresa y en el anticuerpo-anticuerpo con conjugado de entrega dirigido a EGFR (ADC) de su cartera.
ALX Oncology(NASDAQ:ALXO)가 리더십에 상당한 변화를 발표했습니다. 현 이사회 구성원인 Dr. Barbara Klencke가 Interim Chief Medical Officer(CMO)로 임명되어, 회사 이사회로 돌아갈 예비 의장을 맡고 있던 Dr. Alan Sandler를 대체합니다.
Klencke 박사는 종양학 및 신약 개발 분야에서 30년이 넘는 경력을 보유하고 있으며, 2022년 GSK에 인수되기까지 Sierra Oncology의 CMO로 재직한 것을 포함한 주요 성과가 있습니다. 그녀는 ALX의 임상 프로그램인 evorpacept 및 ALX2004의 개발을 감독하며, 회사의 CD47 차단제와 EGFR 표적 항체-약물 결합체(ADC) 파이프라인에 집중할 것입니다.
ALX Oncology (NASDAQ:ALXO) a annoncé un changement important dans sa direction: Dr Barbara Klencke, actuelle membre du conseil, a été nommée Chief Medical Officer (CMO) par intérim, remplaçant Dr Alan Sandler qui retournera à son poste au Conseil d’administration de l’entreprise.
Le Dr Klencke apporte plus de 30 ans d’expérience dans l’oncologie et le développement de médicaments, avec des réalisations notables comme son poste de CMO chez Sierra Oncology jusqu’à son acquisition par GSK en 2022. Elle supervisera le développement des programmes cliniques evorpacept et ALX2004 d’ALX, en se concentrant sur le bloqueur CD47 de l’entreprise et sur l’anticorps-médicament conjugué ciblant l’EGFR (ADC) de la pipeline.
ALX Oncology (NASDAQ:ALXO) hat eine bedeutende Führungsänderung angekündigt: Dr. Barbara Klencke, derzeitiges Vorstandsmitglied, wurde zur Interim Chief Medical Officer (CMO) ernannt und ersetzt damit Dr. Alan Sandler, der an seinen Platz im Vorstand des Unternehmens zurückkehrt.
Dr. Klencke verfügt über mehr als 30 Jahre Erfahrung in der Onkologie und der Arzneimittelentwicklung, darunter eine wichtige Rolle als CMO bei Sierra Oncology bis zur Übernahme durch GSK im Jahr 2022. Sie wird die Entwicklung der klinischen Programme evorpacept und ALX2004 von ALX betreuen und sich auf den CD47-Blocker des Unternehmens sowie auf den EGFR-targeted Antibody-Drug Conjugate (ADC) Pipeline konzentrieren.
أعلنت ALX Oncology (بورصة ناسداك: ALXO) عن تغيير هام في القيادة حيث تم تعيين العديد من الكافر Barbara Klencke كمدير طبي مؤقت (CMO)، لتحل محل الدكتور ألان ساندلر الذي سيعود إلى منصبه في مجلس إدارة الشركة.
تجلب الدكتورة كلينكي أكثر من 30 عامًا من الخبرة في مجال الأورام وتطوير الأدوية، مع إنجازات بارزة منها عملها كـ CMO في Sierra Oncology حتى استحواذ GSK عليها في 2022. ستشرف على تطوير برامج ALX السريرية evorpacept و ALX2004، والتركيز على مثبّت CD47 في الشركة وارتباط EGFR-مجلد الأجسام المضادة الدوائية (ADC) في خط أنابيبها.
ALX Oncology（纳斯达克股票代码：ALXO）宣布重要的领导层变动：现任董事会成员
Klencke 博士在肿瘤学和药物开发领域拥有超过30 年的经验，其中包括在 Sierra Oncology 担任 CMO，直至其在 2022 年被 GSK 收购。她将监督 ALX 的< b>evorpacept 与 ALX2004临床项目的开发，专注于公司的 CD47 阻断剂以及面向 EGFR 的抗体药物偶联物（ADC）管线。
- None.
- Interim nature of the CMO position creates uncertainty about long-term leadership
- Departure of current CMO could potentially impact ongoing clinical programs
- Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company’s Board of Directors and will step down from the Board to join ALX as Interim Chief Medical Officer
- Alan Sandler, M.D. resigns as Chief Medical Officer and will return to his position serving on the Company’s Board of Directors
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced the appointment of Dr. Klencke to the role of Interim Chief Medical Officer (CMO) on a full-time basis. Dr. Alan Sandler is departing from the role of CMO and will return to his former position on the ALX Oncology Board of Directors (BOD), where he previously served.
“Dr. Barbara Klencke’s extensive expertise in driving cancer innovation is evidenced by her substantial contributions to the development and approval of numerous first-in-class therapies, making her well positioned to lead the execution of our Company’s near and longer-term milestones,” said Jason Lettmann, Chief Executive Officer at ALX Oncology. “As a current member of our BOD, she can immediately step into the Interim CMO role to implement our focused development strategy across both the evorpacept and ALX2004 clinical programs. Barbara brings a track record of success with early-stage companies having served as the CMO of Sierra Oncology from 2015 through its acquisition by GlaxoSmithKline (GSK) in 2022. We also thank Alan for his instrumental role as CMO and look forward to his continued contributions to the Company as he returns to his role as a Director on our Board.”
“As a member of ALX Oncology’s Board, I’ve witnessed firsthand the remarkable progress across both the evorpacept and ALX2004 clinical programs,” said Dr. Klencke. “As I step into my new role as Interim CMO, I look forward to working alongside this experienced leadership team as they continue the development of their highly differentiated CD47 blocker and novel epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC). I am excited to drive these molecules forward and deliver on ALX’s commitment to bring clinically meaningful innovation to patients in need.”
An ALX Board member since January 2025, Dr. Klencke has more than 30 years of experience in patient care, academic and scientific research, and clinical drug development in hematology and oncology. She has deep R&D expertise and has made significant contributions to the development, approval and commercialization of numerous oncology products through various executive leadership roles at a range of small, mid-sized and large biotech companies including Sierra Oncology (acquired by GSK), Onyx Pharmaceuticals (acquired by Amgen) and Genentech, a member of the Roche Group. Prior to entering the biotechnology industry, Dr. Klencke served as an Assistant Clinical Professor of Medicine, Division of Hematology and Oncology, at the University of California, San Francisco, where she previously completed her training in hematology, oncology and internal medicine. She holds a Bachelor of Science degree from Indiana University and an M.D. from the University of California, Davis. In addition to ALX Oncology, Dr. Klencke is an independent board director of Xencor and TScan Therapeutics.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and entered the clinic in a Phase 1 trial in August 2025. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objectives of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology’s filings with the Securities and Exchange Commission (“SEC”), including ALX Oncology’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com
Media Contact:
Audra Friis, Sam Brown Healthcare Communications
audrafriis@sambrown.com
(917) 519-9577
FAQ
Who is the new interim CMO of ALX Oncology (NASDAQ:ALXO)?
What experience does Dr. Barbara Klencke bring to ALX Oncology as interim CMO?
What clinical programs will Dr. Klencke oversee at ALX Oncology?
Who did Dr. Barbara Klencke replace as CMO of ALX Oncology?
What is Dr. Klencke's background before joining ALX Oncology?
